Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: J Viral Hepat. 2016 Nov 24;24(5):404–411. doi: 10.1111/jvh.12652

Table 2.

Effect of DAA therapy targeted at HIV-coinfected individuals versus random individuals.

Treatment
efficacy
HIV coinfection-
targeted1
Randomly
targeted1
Prevention yield
improvement2
80% 0.308 0.122 2.525
90% 0.346 0.137 2.530
100% 0.384 0.153 2.514
1

Median number of prevented infections per targeted individual

2

Ratio of median number of prevented infections between HIV-coinfection targeted and randomly delivered DAA therapy